marked.bio

PD-1/IL-2α-bias fusion protein · fusion protein

IBI363

2 active trials across 3 of our biomarkers, targeting PD-1 / IL-2. Not approved for any biomarker on marked.bio yet.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
EGFR exon 19 deletion / L858R 2 2 Phase 2
ALK fusion 1 1 Phase 1/2
RET fusion or mutation 1 1 Phase 1/2

Sponsors

Industry sponsors leading active biomarker-selected trials of IBI363.

  1. Innovent Biologics 1

Trials

2 of 2 trials shown

  1. A Study of IBI363 Combination Therapy in Participants With Advanced Solid Tumors

    Not yet recruiting Phase 2 Innovent Biologics Started 2025Primary completion 2026-09 NCT07124793

    IBI363

    Documented EGFR mutation (ex19del or L858R) detected in tumor tissue or blood samples;

    EGFR exon 19 deletion / L858REGFR Mutant NSCLC and Platinum Resistant Ovarian Cancer

  2. The Efficacy and Safety of IBI363 in Solid Tumors

    Recruiting Phase 1/2 Hunan Province Tumor Hospital Started 2023Primary completion 2026-12 NCT06081907

    IBI363lenvatinib

    …F: Patients with histological or cytological confirmation of advanced NSCLC who harboring EGFR mutation and failed standard treatment.

    EGFR exon 19 deletion / L858RALK fusionRET fusion or mutationStatus may be outdated, last updated 2024-05-30Advanced Solid Tumor